Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications
Jaguar Health (NASDAQ:JAGX) announced that its joint venture, Magdalena Biosciences, has successfully imported 6 kilograms of coca leaf from Peru to Filament's Vancouver facility. The import, authorized by Peru's Health Authority DIGEMID and sourced from ENACO, marks Magdalena's second coca leaf import into Canada.
The initiative aims to develop novel plant-based prescription medicines for mental health conditions, particularly exploring coca leaf's therapeutic potential for ADHD and other neuropsychiatric indications. Dr. Steven King, Jaguar's Chief Sustainable Supply Officer, will present on coca-based Botanical Drugs at the Wisdom of the Leaf Coca Summit in February 2025.
Magdalena's mission focuses on developing FDA-approved plant-based drugs for conditions including schizophrenia, anxiety, depression, and ADHD, emphasizing potentially safer alternatives to traditional medications that may have side effects.
Jaguar Health (NASDAQ:JAGX) ha annunciato che la sua joint venture, Magdalena Biosciences, ha importato con successo 6 chilogrammi di foglie di coca dal Perù presso la struttura di Filament a Vancouver. L'importazione, autorizzata dall'Autorità Sanitaria del Perù, DIGEMID, e proveniente da ENACO, segna la seconda importazione di foglie di coca da parte di Magdalena in Canada.
L'iniziativa mira a sviluppare nuovi medicinali prescritti a base vegetale per condizioni di salute mentale, esplorando in particolare il potenziale terapeutico delle foglie di coca per ADHD e altre indicazioni neuropsichiatriche. Il Dr. Steven King, Chief Sustainable Supply Officer di Jaguar, presenterà i farmaci botanici a base di coca al Wisdom of the Leaf Coca Summit nel febbraio 2025.
La missione di Magdalena si concentra sullo sviluppo di farmaci a base vegetale approvati dalla FDA per condizioni come schizofrenia, ansia, depressione e ADHD, sottolineando alternative potenzialmente più sicure rispetto ai farmaci tradizionali che possono avere effetti collaterali.
Jaguar Health (NASDAQ:JAGX) anunció que su empresa conjunta, Magdalena Biosciences, ha importado con éxito 6 kilogramos de hoja de coca desde Perú a la instalación de Filament en Vancouver. La importación, autorizada por la Autoridad Sanitaria de Perú, DIGEMID, y provista por ENACO, marca la segunda importación de hojas de coca de Magdalena en Canadá.
La iniciativa busca desarrollar nuevos medicamentos recetados a base de plantas para condiciones de salud mental, explorando especialmente el potencial terapéutico de la hoja de coca para ADHD y otras indicaciones neuropsiquiátricas. El Dr. Steven King, Director de Suministro Sostenible de Jaguar, presentará sobre los medicamentos botánicos a base de coca en la Cumbre de Sabiduría de la Hoja de Coca en febrero de 2025.
La misión de Magdalena se centra en el desarrollo de medicamentos a base de plantas aprobados por la FDA para afecciones como esquizofrenia, ansiedad, depresión y ADHD, enfatizando alternativas potencialmente más seguras a los medicamentos tradicionales que pueden tener efectos secundarios.
재규어 헬스 (NASDAQ:JAGX)는 자사의 합작 투자사인 막달레나 바이오사이언스가 페루에서 6킬로그램의 코카 잎을 성공적으로 캐나다 팬더먼트의 시설로 수입했다고 발표했습니다. 이 수입은 페루의 보건 당국인 DIGEMID에 의해 허가되었으며, ENACO에서 공급된 코카 잎의 두 번째 수입입니다.
이 프로젝트는 정신 건강 상태에 대한 새로운 식물 기반 처방 의약품을 개발하는 것을 목표로 하며, 특히 ADHD 및 기타 신경정신과적 증상에 대한 코카 잎의 치료 잠재력을 탐구하고 있습니다. 재규어의 지속 가능한 공급 책임자인 스티븐 킹 박사는 2025년 2월 와이즈덤 오브 더 리프 코카 서밋에서 코카 기반 식물 약물에 대해 발표할 예정입니다.
막달레나의 사명은 조현병, 불안, 우우울증 및 ADHD와 같은 조건에 대해 FDA 승인을 받은 식물 기반 약물을 개발하는 데 초점을 맞추고 있으며, 부작용이 있을 수 있는 전통적인 약물에 대한 잠재적으로 더 안전한 대안을 강조하고 있습니다.
Jaguar Health (NASDAQ:JAGX) a annoncé que sa coentreprise, Magdalena Biosciences, a réussi à importer 6 kilogrammes de feuilles de coca du Pérou vers l'installation de Filament à Vancouver. L'importation, autorisée par l'Autorité de santé péruvienne, DIGEMID, et provenant d'ENACO, marque la deuxième importation de feuilles de coca par Magdalena au Canada.
Cette initiative vise à développer de nouveaux médicaments prescrits à base de plantes pour des problèmes de santé mentale, en explorant en particulier le potentiel thérapeutique des feuilles de coca pour le TDAH et d'autres indications neuropsychiatriques. Le Dr Steven King, directeur de l'approvisionnement durable chez Jaguar, présentera des médicaments botaniques à base de coca lors du Wisdom of the Leaf Coca Summit en février 2025.
La mission de Magdalena se concentre sur le développement de médicaments à base de plantes approuvés par la FDA pour des affections telles que la schizophrénie, l'anxiété, la dépression et le TDAH, soulignant des alternatives potentiellement plus sûres aux médicaments traditionnels pouvant avoir des effets secondaires.
Jaguar Health (NASDAQ:JAGX) gab bekannt, dass ihr Joint Venture, Magdalena Biosciences, erfolgreich 6 Kilogramm Koka-Blätter aus Peru in die Filament-Anlage in Vancouver importiert hat. Der Import, der von der peruanischen Gesundheitsbehörde DIGEMID genehmigt und von ENACO bezogen wurde, markiert Magdalenas zweiten Koka-Blatt-Import nach Kanada.
Die Initiative zielt darauf ab, neuartige pflanzenbasierte verschreibungspflichtige Medikamente für psychische Erkrankungen zu entwickeln, insbesondere das therapeutische Potenzial von Koka-Blättern für ADHS und andere neuropsychiatrische Indikationen zu erkunden. Dr. Steven King, Chief Sustainable Supply Officer von Jaguar, wird im Februar 2025 beim Wisdom of the Leaf Coca Summit über kokabasierten pflanzlichen Arzneimitteln sprechen.
Magdalenas Mission konzentriert sich auf die Entwicklung von FDA-zugelassenen pflanzenbasierten Medikamenten für Erkrankungen wie Schizophrenie, Angst, Depression und ADHS und betont potenziell sicherere Alternativen zu traditionellen Medikamenten, die Nebenwirkungen haben können.
- None.
- None.
Magdalena to explore coca leaf's possible therapeutic benefit for treatment of potentially ADHD or other neuropsychiatric indications
The import was conducted in collaboration with the government of Peru
Steven King, Ph.D. of Jaguar to speak about the potential promise of coca-based Botanical Drugs at the February 2025 Wisdom of the Leaf Coca Summit in Peru
Magdalena is focused on developing novel, natural prescription medicines derived from plants for mental health indications
SAN FRANCISCO, CA / ACCESSWIRE / December 19, 2024 / Jaguar Health, Inc.(NASDAQ:JAGX) ("Jaguar") today announced that Magdalena Biosciences, Inc. ("Magdalena"), a joint venture formed by Jaguar and Filament Health Corp. (OTCQB:FLHLF)(Cboe CA:FH)(FSE:7QS) ("Filament" or "Filament Health"), successfully completed an import of six kilograms of coca leaf from Peru to Filament's Metro Vancouver research and development facility. This is the second import of coca leaf into Canada that Magdalena has completed. It was authorized by the Peruvian Health Authority, Dirección General de Medicamentos Insumos y Drogas (DIGEMID), and acquired from the Empresa Nacional de la Coca (ENACO), the only company in Peru authorized to distribute coca leaf.
Image of coca leaves. © Steven King, Ph.D.
"We are pleased to partner with Filament Health and Magdalena to facilitate this second import of coca leaf," said Silveria Dongo Gonzales, Technical Director of ENACO. "We appreciate Filament and Magdalena's diligent efforts in maintaining a productive relationship with ENACO."
"We are delighted to be continuing our collaboration and partnership with ENACO and the people who hold the coca leaf sacred as part of their daily lives in the Andean region of Peru," said Steven King, Ph.D., Jaguar's Chief Sustainable Supply and Ethnobotanical Research Officer and an Advisor to Magdalena. "We believe that the development of Botanical Drugs from ‘whole extract' coca leaf can provide therapeutic benefit, and that the development process will benefit the people of Peru, who have been sustainably producing coca leaves for several thousand years."
Dr. King will be presenting more details about the potential promise of whole extract coca leaf Botanical Drugs at The McKenna Academy of Natural Philosophy's groundbreaking Wisdom of the Leaf Coca Summit, which takes place February 3-7, 2025 in Peru.
Magdalena's mission is to develop novel, safe, efficacious next-generation psychoactive FDA-approved plant-based drugs under FDA Botanical Guidance for mental health indications including schizophrenia, anxiety, depression, and cognitive deficits in attention-deficit/hyperactivity disorder (ADHD). The coca leaf imported from Peru will be used for the development of a Botanical Drug candidate for the treatment of potentially ADHD or other neuropsychiatric indications.
"By importing this significant volume of raw material, we are able to begin the important work of exploring coca leaf's therapeutic potential for the treatment of ADHD," said Benjamin Lightburn, Chief Executive Officer of Filament Health and Magdalena Board Member. "This import was a significant regulatory achievement by our team and we are grateful to the Peruvian government for its ongoing partnership."
"We look forward to Magdalena continuing its pioneering research into the potential medicinal benefits of coca," said Dr. King. "Many commonly used neuropsychiatric prescription medications have side effects such as personality changes or sedation. With centuries of use by Indigenous healers and traditional psychiatrists, plant-derived medicines offer potential new mechanisms of action for treating mental disorders while being potentially safer than the small molecule drugs that may have ‘off target' effects."
"Plant-based drugs offer new opportunities and new mechanisms of action, as highlighted in an article in The New York Times on December 16, 2024 titled "Seeking Relief From Brain Injury, Some Veterans Turn to Psychedelics," which focuses on ibogaine, an alkaloid derived from the bark of the iboga tree," said Dr. Karen Brunke, Jaguar's EVP of Corporate and Business Development and Acting CEO of Magdalena.
ABOUT MAGDALENA BIOSCIENCES
Jaguar Health, Inc. and Filament Health Corp. formed Magdalena Biosciences, Inc. as a joint venture in 2023 to develop novel, natural prescription medicines derived from plants for mental health indications including attention-deficit/hyperactivity disorder (ADHD), depression and anxiety in adults. Boulder, Colorado-based One Small Planet, founded by Will Peterffy, has committed to funding of US
ABOUT FILAMENT HEALTH (OTCQB:FLHLF) (CBOE:FH) (FSE:7QS)
Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. We are paving the way with what we believe to be the first-ever natural psychedelic drug candidates.
Learn more at www.filament.health and on Twitter, Instagram and LinkedIn.
ABOUT THE JAGUAR HEALTH FAMILY OF COMPANIES
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that the coca leaf imported from Peru will be used for development of a Botanical Drug candidate for the treatment of potentially ADHD or other neuropsychiatric indications, Jaguar's expectation that the development of Botanical Drugs from ‘whole extract' coca leaf can provide therapeutic benefit and that the development process will benefit the people of Peru, and Jaguar's expectation that Dr. King will present at the 2025 Wisdom of the Leaf Coca Summit. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact Info:
hello@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on accesswire.com
FAQ
What is the purpose of JAGX's recent coca leaf import from Peru?
How much coca leaf did JAGX's Magdalena Biosciences import from Peru?
What mental health conditions is JAGX targeting with its coca leaf research?
When will JAGX present its coca-based botanical drug research findings?
Which Peruvian authorities approved JAGX's coca leaf import?
